Molbio Diagnostics Limited

Healthcare — Medical Devices · NSE

₹1,568.00+₹138.70 (+9.70%)

DalalBaazaar Score

67 / 100

🟢 Good

Verdict

REASONABLE

Risk

Moderate

Driven by small-cap size, which brings sharper price swings, a very high earnings multiple, which leaves little margin for disappointment.

In simple words: Strong business and financial position, with both sales and profits growing well. Valuation is currently the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:03 pm

Understanding the Business

Company site ↗

The 60-second version of Molbio Diagnostics Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors.

IndustryMedical Devices

SectorHealthcare

Employees1,225

Annual revenue₹1,415 Cr

How does it make money?

Turns over ₹1,415 Cr a year. Of every ₹100 of sales, about ₹12 reaches shareholders as profit, with ₹24 left at the operating level before interest, tax and depreciation. Each of its 1,225 employees supports ₹1.16 Cr of revenue a year, the signature of a capital- or asset-led business.

Revenue / employee₹1.16 Cr

Who are its competitors?

The closest listed comparisons in its industry are SUN PHARMACEUTICAL IND L, CIPLA LTD, DR. REDDY S LABORATORIES, APOLLO HOSPITALS ENTER. L. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Some evidence

ROCE of 16.5% is above what capital typically costs, which suggests some pricing power, though not yet the sustained, wide gap that marks a durable advantage.

Peer median ROE14.5%

What is the outlook?

3 analysts covering the stock expect revenue to grow about 25.3% and earnings to grow about 55.3% in the year to 2028. These are estimates by people who follow the company, not a forecast for the wider industry.

Est. revenue growth+25.3%

Est. earnings growth+55.3%

Analysts3

What has been driving growth?

Profit has moved mainly because margins changed, not because the business sold much more. Over 3 years revenue moved +339% while net margin moved -5329% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+339%

Margin effect-5329%

DalalBaazaar Score

67/ 100

Good

Weighted across six categories. Every point is explained below.

✗ P/E of 108.4x is demanding — it needs sustained high growth to justify
✗ P/B of 15.12x is a steep premium to book

Quality vs. Valuation

Company Quality

81/ 100

Excellent

How good the business is, ignoring the share price entirely.

Valuation

23/ 100

Expensive

What you are being asked to pay, ignoring how good the business is.

A good business, but the price already reflects that. The quality is real; the question is whether you are overpaying for it today.

Historical Valuation

Current P/E

108.4x

Sector Median

33.3x

median of 4 sector peers

⚠️Against its sector it trades 225% above the peer median of 33.3x.

vs. its own history

Not enough price and earnings history

vs. sector peers

Expensive

33.3x median of 4 peers · +225%

vs. generic bands

Expensive

Above 35x

EV/EBITDA

53.3x

PEG

7.32

What's Good / What's Bad

🟢 What's Going Well3

Margins are improving
EBITDA margin is up from 15.4% to 24.1% over 3 years.
Return on equity is rising
ROE has improved from -0.1% to 14.2%.
Return on capital is rising
ROCE has improved from 2.1% to 16.5%.

🔴 What Needs Attention0

Nothing stands out as clearly deteriorating on the years of data available.

Red Flags

2 items require attention · 2 high

🔴Debt has risen sharplyFinancial
Total debt is up 280% over 3 years, from ₹119 Cr to ₹450 Cr.
🔴Profit up while operating cash flow fallsFinancial
Reported profit rose but cash generated by operations declined — worth checking whether earnings are being supported by non-cash items or working capital.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Margin expansion has further to run
EBITDA margin has risen from 15.4% to 24.1%. If that holds, profit compounds faster than sales and today's multiple looks cheaper in hindsight than it does now.
Self-funding with balance-sheet headroom
Positive free cash flow of ₹0 Cr alongside low debt means growth, buybacks or dividends need no outside money — and a downturn can be absorbed rather than refinanced.

🔴 Bear CaseWhat could go wrong?

A premium to the sector to defend
It trades 225% above the peer median. That premium needs a reason that persists, or it closes.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Small Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.
Several serious flags at once
2 high-severity checks triggered. Individually each has an explanation; together they raise the chance that something structural is wrong rather than a one-off.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 48% a year✓ 63.7% CAGR
Latest reported year was 309.6%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2EBITDA margin holds above 22%✓ 24.1%
Two points below today's level — enough room for noise, tight enough to catch real compression.
3Free cash flow remains positive✓ ₹0 Cr
Profit that never becomes cash eventually stops being profit.
4Debt / EBITDA stays below 2x✓ 1.3x
The ratio lenders write covenants against; it survives a small or negative equity base, unlike Debt/Equity.
5ROCE stays above 14%✓ 16.5%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

9 / 11 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✓ Strong return on capital employed (ROCE ≥ 15%)
✓ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✗ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✓ Analyst consensus isn't majority-sell

Price history

Quick Metrics

6 good · 3 neutral · 2 weak

Market Cap

₹18,070 Cr

Small Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

108.4x

Expensive

Expensive — verify against sector peers

P/B Ratio

15.12x

Rich

Steep premium to book — needs high, durable returns to justify

EPS (TTM)

₹14.46

Profitable

Profitable on a per-share basis

ROE

14.2%

Moderate

Moderate capital efficiency

ROCE

16.5%

Strong

Earns comfortably above its likely cost of capital

Debt/Equity

0.34x

Low

Conservative leverage

Revenue Growth (YoY)

309.6%

Healthy

Healthy top-line growth

Profit Growth (YoY)

14.8%

Healthy

Profits growing at a healthy clip

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

₹0 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

P/E (Forward)

43.7x

Improving

Below the trailing multiple — the street expects earnings to grow into the price

Operating Margin

20.4%

Good

Healthy core-business profitability

Net Margin

14.2%

Good

Strong bottom-line conversion

Current Ratio

2.48

Comfortable

Healthy short-term liquidity

52W Range Position

84%

Mid-range

Technical Snapshot

RSI (14)

74.6

Overbought zone

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹322 Cr	₹820 Cr	₹997 Cr	₹1,415 Cr	+63.7%
EBITDA	₹50 Cr	₹258 Cr	₹273 Cr	₹341 Cr	+90.0%
EBITDA Margin	15.4%	31.5%	27.4%	24.1%	—
PAT (Net Profit)	-₹1 Cr	₹102 Cr	₹145 Cr	₹167 Cr	—
ROE	-0.1%	12.4%	15.0%	14.2%	—
ROCE	2.1%	16.3%	20.6%	16.5%	—
Total Debt	₹119 Cr	₹184 Cr	₹147 Cr	₹450 Cr	+56.0%
Free Cash Flow	₹50 Cr	-₹7 Cr	₹232 Cr	₹0 Cr	-80.6%

🟢 Revenue has grown at 63.7% a year over 3 years.

🟢 EBITDA has grown at 90.0% a year over 3 years.

🟢 EBITDA Margin has risen from 15.4% to 24.1% over 3 years (+8.7 pts).

🟢 PAT (Net Profit) has turned positive, from -₹1 Cr to ₹167 Cr.

🟢 ROE has risen from -0.1% to 14.2% over 3 years (+14.3 pts).

🟢 ROCE has risen from 2.1% to 16.5% over 3 years (+14.4 pts).

🔴 Total Debt has grown at 56.0% a year over 3 years.

🔴 Free Cash Flow has shrunk at 80.6% a year over 3 years.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹2,148 Cr

Total Liabilities

₹840 Cr

Cash & Equivalents

₹356 Cr

Operating Cash Flow

₹50 Cr

Capex

-₹50 Cr

Shareholding (proxy)

Institutional Holding

9.7%

Insider Holding

80.8%

Analyst Consensus

Recommendations

3 Buy · 0 Hold · 0 Sell

Target Price (Mean)

₹1,650

+5.2% vs CMP

Target Range

₹1,550 – ₹1,800

Peer Comparison

Company	P/E	ROE
SUN PHARMACEUTICAL IND L	34.9x	14.5%
CIPLA LTD	31.8x	9.8%
DR. REDDY S LABORATORIES	31.0x	8.8%
APOLLO HOSPITALS ENTER. L	54.3x	22.0%

Recent News

1 mixed5 general

Molbio Diagnostics shares jump 5% as HDFC MF buys 1.99% stake via bulk deal | Newly listed stock up 71% from IPO price

TradingView, 01 OctPrice move

🟡Mixed / dependsA price move, which is not by itself a change in the business. Worth finding the cause before reading it as either good or bad.

Molbio gains 9% as Jefferies assigns 'Buy' tag on innovation-led model

Business Standard, 30 Sept

Kotak Mahindra Mutual Fund crosses 5% stake in Molbio Diagnostics

scanx.trade, 13 Oct

Molbio Diagnostics Stock Soars 9% As It Becomes Jefferies Top Med Tech Pick At Initiation

NDTV Profit, 30 Sept

Molbio Diagnostics shares zoom over 21% in stock market debut

BusinessLine, 17 Aug

MOLBIO DIAGNOSTICS LTD Share Price

Upstox, 16 Aug

Watch Items

Cross-check against the company's latest quarterly filing / investor presentation before acting.
RSI is in overbought territory — momentum entries here carry more short-term pullback risk.

DalalBaazaar Thesis

StrongBusiness Quality · Financial Health · Growth · Profitability

WeakValuation · Risk

Points for each in the Score ↑

Good business, demanding price

The quality is real and the price already reflects it. Buying here is a bet that the business keeps compounding for long enough to grow into the multiple — which good businesses often do, but it removes the margin for error that a lower price would have given you. 2 high-severity red flags sit above this conclusion and should be read first.

All 5 tripwires holding · see Key things to watch ↑